ArticleFrontiers in immunology2026
mtROS-NF-κB signaling supports ILC3 function and survival during sepsis-induced intestinal injury.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis frequently induces intestinal barrier injury, which exacerbates systemic inflammation, and contributes to high mortality. Group 3 innate lymphoid cells (ILC3s) are key regulators of mucosal immunity, yet their role in sepsis-associated intestinal injury remains incompletely understood. We found circulating ILCPs were reduced in patients with sepsis. In an LPS-induced murine sepsis model, colonic ILC3 numbers declined whereas the residual population showed increased frequencies of IL-22- and GM-CSF-producing cells. RORγt-deficient mice exhibited impaired induction of colonic IL-22 and GM-CSF, increased intestinal permeability, and aggravated histopathological injury. Adoptive transfer of purified wild-type ILC3s restored colonic IL-22 and GM-CSF levels and partially improved barrier integrity. Mechanistically, septic ILC3s showed hypoxia-associated mitochondrial impairment and accumulation of mitochondrial ROS. increased mtROS contributed to enhanced NF-κB p65 phosphorylation and selectively supported IL-22 and GM-CSF production. Recombinant IL-22 or GM-CSF ameliorated intestinal injury. However, ROS scavenging or NF-κB inhibition increased ILC3 apoptosis, indicating that ROS-NF-κB axis also supports residual ILC3 survival. Together, these findings identify a mitochondria-associated ROS-NF-κB program that sustains protective cytokine production and survival in residual intestinal ILC3s during sepsis, although it is insufficient to prevent ongoing ILC3 loss and intestinal injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.